Table 1 Key recommendations

• Lacking clear evidence of efficacy in improving PGT-A outcomes and, indeed, raising concerns about causing possible adverse effects on outcomes in at least some patients, the procedure must be considered experimental.

• Consequently, PGT-A should only be selectively applied within study frameworks and with appropriate informed consent.

• PGT-A should be considered contraindicated in women with small embryo numbers.

• Considering existing evidence for high false-positive rates in describing embryos as chromosomal-abnormal by PGT-A, such embryos should no-longer automatically be disposed of but be maintained in cryopreservation, unless disposal is specifically requested by patients.

• Current knowledge which embryos, by PGT-A designated as chromosomal-abnormal, can be transferred under which outcome expectations, is insufficient, and should be a primary research target.